BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Dr. Reddy’s Unit Shows Promising Trial Results For Blood Cancer Treatment

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Dr. Reddy's subsidiary, Aurigene Oncology, has shown positive results in its Phase 1 clinical trial for blood cancer therapy, with 62.5% of patients achieving a complete response. This marks a significant step forward in cancer treatment.

Dr. Reddy's news today

Aurigene Oncology Limited, a subsidiary of Dr. Reddy’s Laboratories, has reported positive results from its first clinical trial of Ribrecabtagene autoleucel (DRL-1801), a new CAR-T cell therapy for multiple myeloma, a type of blood cancer. This breakthrough in cancer treatment marks a significant milestone as it is the first trial of its kind in India to test CAR-T therapy for this condition.

DR. REDDY S LABORATORIES

Trade

1174.8-25.69 (-2.13 %)

Updated - 25 April 2025
1210.50day high
DAY HIGH
1159.70day low
DAY LOW
729226
VOLUME (BSE)

Clinical trial success

The Phase 1 clinical trial, named the SWASTH study, involved eight patients who had previously undergone multiple treatments for multiple myeloma, with an average of 5.5 prior treatments, including transplants. The trial yielded remarkable results, with all eight patients showing a clinical response to the therapy. Notably, 62.5% of these patients achieved a complete response, demonstrating the potential effectiveness of this new treatment.

Moreover, the therapy exhibited a strong safety profile. None of the patients experienced serious side effects, such as Cytokine Release Syndrome (CRS) or neurotoxicity, which are common concerns in CAR-T cell therapies. These results provide a solid foundation for further research and development.

Moving forward to Phase 2

Following the promising results of the Phase 1 trial, the Drugs Controller General of India (DCGI) has approved the initiation of Phase 2 of the trial, which will involve a larger cohort of patients. This advancement is expected to further evaluate the effectiveness and safety of Ribrecabtagene autoleucel in treating relapsed refractory multiple myeloma patients.

The trial results were recently presented at the 21st annual meeting of the International Myeloma Society in Rio De Janeiro, Brazil, showcasing India’s growing contributions to global cancer research.

With these positive trial outcomes, Aurigene Oncology’s efforts mark a significant advancement in blood cancer treatment. The success of the trial is likely to bolster investor confidence, potentially benefiting Dr. Reddy share price as the company continues its efforts in developing innovative cancer therapies.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

9.5 lakh+ Users

icon-with-text

4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4400+ Cr MTF Book

icon-with-text